Are we getting closer to the treatment of rabies?

Future Virology

Volumn 4, Issue 6, 2009, Pages 563-570

  Willoughby Jr , Rodney E ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Dopamine; Encephalitis; Immunology; Nimodipine; Quinolinic acid; Rabies; Ribavirin; Serotonin; Tetrahydrobiopterin; Vaccine; Vasospasm; Zoonosis

Indexed keywords

AMANTADINE; DIZOCILPINE; GAMMA INTERFERON; KETAMINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NICOTINIC RECEPTOR; NIMODIPINE; NITRIC OXIDE SYNTHASE; RABIES VACCINE; RIBAVIRIN; SAPROPTERIN; STAT1 PROTEIN; TETRAHYDROBIOPTERIN; UBIDECARENONE;

ATRIOVENTRICULAR BLOCK; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN EDEMA; BRAIN VASOSPASM; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; DYSAUTONOMIA; HUMAN; IMMUNE RESPONSE; LACTIC ACIDOSIS; METABOLOMICS; MORTALITY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PHENYLKETONURIA; PRIORITY JOURNAL; RABIES; REVIEW; SEDATION; SINGLE DRUG DOSE; SUBARACHNOID HEMORRHAGE; SURVIVAL RATE; VIRUS LOAD; VIRUS PATHOGENESIS; ZOONOSIS;

EID: 73949129744     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.09.52     Document Type: Review

References (56)

1. Pasteur L: Resultats de l'application de la methode pour prevenir la rage apres morsure. C. R. Acad. Sci. 102, 459-466 (1886).
2. Rupprecht CE, Gibbons RV: Clinical practice. Prophylaxis against rabies. N. Engl. J. Med. 351(25), 2626-2635 (2004).
3. Mallewa M, Fooks AR, Banda D et al.: Rabies encephalitis in malaria-endemic area, Malawi, Africa. Emerg. Infect. Dis. 13(1), 136-139 (2007).
4. Dietzschold B, Li J, Faber M, Schnell M: Concepts in the pathogenesis of rabies. Future Virol. 3(5), 481-490 (2008).
5. Scott CA, Rossiter JP, Andrew RD, Jackson AC: Structural abnormalities in neurons are sufficient to explain clinical disease and fatal outcome of experimental rabies in yellow fluorescent protein-expressing transgenic mice. J. Virol. 82(1), 513-521 (2008).
6. Li XQ, Sarmento L, Fu ZF: Degeneration of neuronal processes after infection with pathogenic, but not attenuated, rabies viruses. J. Virol. 79(15), 10063-10068 (2005).
7. Charlton KM, Casey GA: Experimental rabies in skunks: immunofluorescence light and electron microscopic studies. Lab. Invest. 41(1), 36-44 (1979).
8. Hattwick MA, Weis TT, Stechschulte CJ, Baer GM, Gregg MB: Recovery from rabies. A case report. Ann. Intern. Med. 76(6), 931-942 (1972).
9. Porras C, Barboza JJ, Fuenzalida E, Adaros HL, Oviedo AM, Furst J: Recovery from rabies in man. Ann. Intern. Med. 85(1), 44-48 (1976).
10. Willoughby RE Jr, Tieves KS, Hoffman GM et al.: Survival after treatment of rabies with induction of coma. N. Engl. J. Med. 352(24), 2508-2514 (2005).
11. Donnelly-Roberts DL, Lentz TL: Synthetic peptides of neurotoxins and rabies virus glycoprotein behave as antagonists in a functional assay for the acetylcholine receptor. Pept. Res. 2(3), 221-226 (1989).
12. Dumrongphol H, Srikiatkhachorn A, Hemachudha T, Kotchabhakdi N, Govitrapong P: Alteration of muscarinic acetylcholine receptors in rabies viralinfected dog brains. J. Neurol. Sci. 137(1), 1-6 (199 6).
13. Willoughby RE Jr, Opladen T, Maier T et al.: Tetrahydrobiopterin deficiency in human rabies. J. Inherit. Metab. Dis. 32(1), 65-72 (2008). ■ Confirms that human rabies is, in part, a disorder of neurotransmission.
14. Willoughby RE, Opladen T: Serum phenylalanine concentrations in patients post trauma and burn correlate to neopterin concentrations - author reply. J. Inherit. Metab. Dis. 32(4), 588 (2009).
15. Vidy A, El Bougrini J, Chelbi-Alix MK, Blondel D: The nucleocytoplasmic rabies virus P protein counteracts interferon signaling by inhibiting both nuclear accumulation and DNA binding of STAT1. J. Virol. 81(8), 4255-4263 (2007).
16. Griffin DE: Immune responses to RNA-virus infections of the CNS. Nat. Rev. Immunol. 3(6), 493-502 (2003). ■ Excellent review on brain immunology, in particular the noncytolytic clearance of RNA viruses.
17. Dietzschold B, Kao M, Zheng YM et al.: Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc. Natl Acad. Sci. USA 89(15), 7252-7256 (199 2). ■■ Underlooked key article on noncytolytic clearance of rabies virus once present in the brain.
18. Phares TW, Fabis MJ, Brimer CM, Kean RB, Hooper DC: A peroxynitritedependent pathway is responsible for blood-brain barrier permeability changes during a central nervous system inflammatory response: TNF-a is neither necessary nor sufficient. J. Immunol. 178(11), 7334-7343 (2007).
19. Willoughby RE, Saxinger L, Rubin J et al.: Metabolomics of human rabies. Presented at: XIX International Conference on Rabies in the Americas. Atlanta, Georgia, USA, 28 September-3 October 2008 (Abstract).
20. Bakker AB, Marissen WE, Kramer RA et al.: Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J. Virol. 79(14), 9062-9068 (2005).
21. Faber M, Li J, Kean RB, Hooper DC, Alugupalli KR, Dietzschold B: Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl Acad. Sci. USA 106(27), 11300-11305 (2009).
22. Willoughby RE Jr: "Early death" and the contraindication of vaccine during treatment of rabies. Vaccine (2009) (In press).
23. Prabhakar BS, Nathanson N: Acute rabies death mediated by antibody. Nature 290(5807), 590-591 (1981).
24. Moghaddam A, Olszewska W, Wang B et al.: A potential molecular mechanism for hypersensitivity caused by formalininactivated vaccines. Nat. Med. 12(8), 905-907 (2006).
25. Hemachudha T, Sunsaneewitayakul B, Mitrabhakdi E et al.: Paralytic complications following intravenous rabies immune globulin treatment in a patient with furious rabies. Int. J. Infect. Dis. 7(1), 76-77 (2003).
26. Jackson AC, Warrell MJ, Rupprecht CE et al.: Management of rabies in humans. Clin. Infect. Dis. 36(1), 60-63 (2003).
27. Lockhart BP, Tordo N, Tsiang H: Inhibition of rabies virus transcription in rat cortical neurons with the dissociative anesthetic ketamine. Antimicrob. Agents Chemother. 36(8), 1750-1755 (199 2).
28. Hu WT, Willoughby RE Jr, Dhonau H, Mack KJ: Long-term follow-up after treatment of rabies by induction of coma. N. Engl. J. Med. 357(9), 945-946 (2007).
29. Gourmelon P, Briet D, Clarencon D, Court L, Tsiang H: Sleep alterations in experimental street rabies virus infection occur in the absence of major EEG abnormalities. Brain Res. 554(1-2), 159-165 (199 1).
30. Ubol S, Kasisith J, Mitmoonpitak C, Pitidhamabhorn D: Screening of upregulated genes in suckling mouse central nervous system during the disease stage of rabies virus infection. Microbiol. Immunol. 50(12), 951-959 (2006).
31. Wang ZW, Sarmento L, Wang Y et al.: Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system. J. Virol. 79(19), 12554-12565 (2005).
32. Wilde H, Hemachudha T, Jackson AC: Viewpoint: management of human rabies. Trans. R. Soc. Trop. Med. Hyg. 102(10), 979-982 (2008).
33. Willoughby RE, Maier T, Rupprecht CE et al.: Biopterin deficiency in human rabies. Presented at: XVII International Conference on Rabies in the Americas. Brasilia, Brazil, 15-22 October 2006 (Abstract).
34. Toda N, Tanaka T, Ayajiki K, Okamura T: Cerebral vasodilatation induced by stimulation of the pterygopalatine ganglion and greater petrosal nerve in anesthetized monkeys. Neuroscience 96(2), 393-398 (2000).
35. Akaike T, Weihe E, Schaefer M et al.: Effect of neurotropic virus infection on neuronal and inducible nitric oxide synthase activity in rat brain. J. Neurovirol. 1(1), 118-125 (1995).
36. Willoughby RE, Roy-Burman A, Martin KW et al.: Generalized cranial artery spasm in human rabies. Dev. Biol. (Basel) 131, 367-375 (2008).
37. Rossiter JP, Hsu L, Jackson AC: Selective vulnerability of dorsal root ganglia neurons in experimental rabies after peripheral inoculation of CVS-11 in adult mice. Acta Neuropathol. 118(2), 249-259 (2009).
38. Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT, Stephen EL: Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 141(5), 580-589 (1980).
39. Neuwelt EA, Kikuchi K, Hill SA, Lipsky P, Frenkel E: Barbiturate inhibition of lymphocyte function. Differing effects of various barbiturates used to induce coma. J. Neurosurg. 56(2), 254-259 (1982).
40. Warrell DA, Davidson NM, Pope HM et al.: Pathophysiologic studies in human rabies. Am. J. Med. 60(2), 180-190 (1976).
41. Keilhoff G, Wolf G, Stastny F: Effects of MK-801, ketamine and alaptide on quinolinate models in the maturing hippocampus. Neuroscience 42(2), 379-385 (1991).
42. Holland JF: Hopes for tomorrow versus realities of today: therapy and prognosis in acute lymphocytic leukemia of childhood. Pediatrics 45(2), 191-193 (1970).
43. Saha V: Simplifying treatment for children with ALL. Lancet 369(9556), 82-83 (2007).
44. Pengsaa K, Limkittikul K, Sabchareon A et al.: A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine. Pediatr. Infect. Dis. J. 28(4), 335-337 (2009).
45. Bakker AB, Python C, Kissling CJ et al.: First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 26(47), 5922-5927 (2008).
46. Zinsstag J, Schelling E, Roth F, Bonfoh B, de Savigny D, Tanner M: Human benefits of animal interventions for zoonosis control. Emerg. Infect. Dis. 13(4), 527-531 (2007).
47. Knowles MK, Roberts D, Craig S, Sheen M, Nadin-Davis SA, Wandeler AI: In vitro and in vivo genetic stability studies of a human adenovirus type 5 recombinant rabies glycoprotein vaccine (ONRAB). Vaccine 27(20), 2662-2668 (2009).
48. Tordo N, Foumier A, Jallet C, Szelechowski M, Klonjkowski B, Eloit M: Canine adenovirus based rabies vaccines. Dev. Biol. (Basel) 131, 467-476 (2008).
49. Zhang S, Liu Y, Fooks AR, Zhang F, Hu R: Oral vaccination of dogs (Canis familiaris) with baits containing the recombinant rabies-canine adenovirus type-2 vaccine confers long-lasting immunity against rabies. Vaccine 26(3), 345-350 (2008).
50. Li J, Faber M, Papaneri A et al.: A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. Virology 356(1-2), 147-154 (2006).
51. Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD et al.: Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455(7212), 532-536 (2008).
52. Roy A, Hooper DC: Immune evasion by rabies viruses through the maintenance of blood-brain barrier integrity. J. Neurovirol. 14(5), 401-411 (2008).
53. Willoughby RE Jr, Long SS: Encephalitis, meningoencephalitis, acute disseminated encephalomyelitis, and acute necrotizing encephalopathy. In: Principles and Practice of Pediatric Infectious Diseases. Long SS, Pickering LK, Prober CG (Eds). Churchill Livingstone, NY, USA (2008).
54. Curry SH: Why have so many drugs with stellar results in laboratory stroke models failed in clinical trials? A theory based on allometric relationships. Ann. NY Acad. Sci. 99 3, 69-74 (2003).
55. One Health Initiative. www.onehealthinitiative.com
56. Rabies registry. www.mcw.edu/rabies